Expanding the horizons of antiplatelet therapy. A pilot study of the antiplatelet properties of a new tropane alkaloid

Introduction. The article discusses the search for new and highly effective drugs for the prevention and treatment of cerebrovascular disease. The  aim was to examine the effect of the acyl hydrazone tropane derivative on individual platelet aggregation (PA) sensitivity in in vitro studies. Results . We present the results of a pilot study on the effect of a new acyl hydrazone tropane derivative — acyl hydrazone (2,3,4-trimethoxy-N'-(8-methyl-8-azabicyclo [3.2.1.] octane-3-ylidene) benzohydrazide hydrochloride on PA properties in vitro in healthy volunteers and in patients with chronic cerebrovascular disease. Conclusion . The studied compound has a pronounced ability to suppress PA when administered intravenously in vivo in two concentrations, equivalent to doses of 10 and 100 mg/kg, and its effect is superior to the comparator acetylsalicylic acid, which is used in clinical practice as an antiplatelet drug.